{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:12:41Z","timestamp":1790878361659,"version":"4.1.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02587-9","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:33:58Z","timestamp":1770305638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Julien","family":"Boudreault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Rahimirad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie Chaltel","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Poulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiou","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Lebrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2587_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"2587_CR2","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"2587_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4:1\u201314.","journal-title":"JAMA Netw Open"},{"key":"2587_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S2468-1253(19)30416-9","volume":"5","author":"SP Pereira","year":"2020","unstructured":"Pereira SP, et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020;5:698\u2013710.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2587_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73\u201385.","journal-title":"Lancet"},{"key":"2587_CR6","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38:1763\u201373.","journal-title":"J Clin Oncol"},{"key":"2587_CR7","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"2587_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011\u201324.","journal-title":"Lancet"},{"key":"2587_CR9","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, et al. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2021-004485"},{"key":"2587_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa2405008","volume":"392","author":"AM Schram","year":"2025","unstructured":"Schram AM, et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med. 2025;392:566\u201376.","journal-title":"N Engl J Med"},{"key":"2587_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350.","journal-title":"Nature"},{"key":"2587_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0109-y","author":"EA Collisson","year":"2019","unstructured":"Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019. https:\/\/doi.org\/10.1038\/s41575-019-0109-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2587_CR13","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.","journal-title":"Nat Rev Dis Primers"},{"key":"2587_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","volume":"29","author":"J Liu","year":"2022","unstructured":"Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Ther. 2022;29:875\u20138.","journal-title":"Cancer Gene Ther"},{"key":"2587_CR15","first-page":"36","volume":"39","author":"H Ying","year":"2025","unstructured":"Ying H, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2025;39:36\u201363.","journal-title":"Genes Dev"},{"key":"2587_CR16","doi-asserted-by":"publisher","first-page":"8696","DOI":"10.1038\/s41467-025-63718-2","volume":"16","author":"VS Kalluri","year":"2025","unstructured":"Kalluri VS, et al. Engineered exosomes with Kras(G12D) specific siRNA in pancreatic cancer: a phase i study with immunological correlates. Nat Commun. 2025;16:8696.","journal-title":"Nat Commun"},{"key":"2587_CR17","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","volume":"163","author":"T Hart","year":"2015","unstructured":"Hart T, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163:1515\u201326.","journal-title":"Cell"},{"key":"2587_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84\u20137.","journal-title":"Science"},{"key":"2587_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.1246981","volume":"343","author":"T Wang","year":"2014","unstructured":"Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2014;343:80\u20134.","journal-title":"Science"},{"key":"2587_CR20","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1038\/s41467-021-23316-4","volume":"12","author":"M Dai","year":"2021","unstructured":"Dai M, et al. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR\/Hippo targeted combination therapy. Nat Commun. 2021;12:3055.","journal-title":"Nat Commun"},{"key":"2587_CR21","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.cell.2015.02.038","volume":"160","author":"S Chen","year":"2015","unstructured":"Chen S, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160:1246\u201360.","journal-title":"Cell"},{"key":"2587_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan FM, et al. Prioritization of cancer therapeutic targets using CRISPR\u2013Cas9 screens. Nature. 2019;568:511\u20136.","journal-title":"Nature"},{"key":"2587_CR23","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.celrep.2017.01.031","volume":"18","author":"B Wang","year":"2017","unstructured":"Wang B, et al. ATXN1L, CIC, and ETS transcription factors modulate sensitivity to MAPK pathway inhibition. Cell Rep. 2017;18:1543\u201357.","journal-title":"Cell Rep"},{"key":"2587_CR24","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1038\/s41467-018-06676-2","volume":"9","author":"K Szlachta","year":"2018","unstructured":"Szlachta K, et al. Crispr knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun. 2018;9:4275.","journal-title":"Nat Commun"},{"key":"2587_CR25","doi-asserted-by":"crossref","unstructured":"Zhong Z, Harmston N, Wood KC, Madan B, Virshup DM. A p300\/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models. J. Clin. Invest. 2022;132.","DOI":"10.1172\/JCI156305"},{"key":"2587_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/1535-7163.MCT-21-0474","volume":"21","author":"D Thummuri","year":"2022","unstructured":"Thummuri D, et al. Overcoming gemcitabine resistance in pancreatic cancer using the BCL-XL\u2013specific degrader DT2216. Mol Cancer Ther. 2022;21:184\u201392.","journal-title":"Mol Cancer Ther"},{"key":"2587_CR27","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1186\/s12885-021-08388-1","volume":"21","author":"RC Ramaker","year":"2021","unstructured":"Ramaker RC, et al. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition. BMC Cancer. 2021;21:632.","journal-title":"BMC Cancer"},{"key":"2587_CR28","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s43018-021-00326-1","volume":"3","author":"C Falcomat\u00e0","year":"2022","unstructured":"Falcomat\u00e0 C, et al. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nat Cancer. 2022;3:318\u201336.","journal-title":"Nat Cancer"},{"key":"2587_CR29","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1038\/s41388-019-0908-1","volume":"38","author":"Z Zhong","year":"2019","unstructured":"Zhong Z, et al. Porcn inhibition synergizes with PI3K\/mTOR inhibition in Wnt-addicted cancers. Oncogene. 2019;38:6662\u201377.","journal-title":"Oncogene"},{"key":"2587_CR30","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/1535-7163.MCT-19-1131","volume":"19","author":"CK Milton","year":"2020","unstructured":"Milton CK, et al. A genome-scale CRISPR screen identifies the ERBB and mTOR signaling networks as key determinants of response to PI3K inhibition in pancreatic cancer. Mol Cancer Ther. 2020;19:1423\u201335.","journal-title":"Mol Cancer Ther"},{"key":"2587_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-07967-6","volume":"21","author":"R Du","year":"2021","unstructured":"Du R, Sullivan DK, Azizian NG, Liu Y, Li Y. Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells. BMC Cancer. 2021;21:1\u201313.","journal-title":"BMC Cancer"},{"key":"2587_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13046-022-02443-w","volume":"41","author":"S Zeng","year":"2022","unstructured":"Zeng S, et al. Cdk7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. J Exp Clin Cancer Res. 2022;41:241.","journal-title":"J Exp Clin Cancer Res"},{"key":"2587_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-44089-3","volume":"9","author":"A Sarr","year":"2019","unstructured":"Sarr A, et al. Genome-scale CRISPR\/Cas9 screen determines factors modulating sensitivity to protide NUC-1031. Sci Rep. 2019;9:1\u201313.","journal-title":"Sci Rep"},{"key":"2587_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-55893-2","volume":"9","author":"M Masoudi","year":"2019","unstructured":"Masoudi M, Seki M, Yazdanparast R, Yachie N, Aburatani H. A genome-scale CRISPR\/Cas9 knockout screening reveals SH3D21 as a sensitizer for gemcitabine. Sci Rep. 2019;9:1\u20139.","journal-title":"Sci Rep"},{"key":"2587_CR35","doi-asserted-by":"publisher","first-page":"28068","DOI":"10.1073\/pnas.2009899117","volume":"117","author":"X Wei","year":"2020","unstructured":"Wei X, et al. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. Proc Natl Acad Sci U S A. 2020;117:28068\u201379.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2587_CR36","doi-asserted-by":"publisher","first-page":"10813","DOI":"10.3748\/wjg.v20.i31.10813","volume":"20","author":"D Kyuno","year":"2014","unstructured":"Kyuno D. Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer. World J Gastroenterol. 2014;20:10813\u201324.","journal-title":"World J Gastroenterol"},{"key":"2587_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/00006676-200410000-00016","volume":"29","author":"SA Rajasekaran","year":"2004","unstructured":"Rajasekaran SA, et al. HPAF-II, a cell culture model to study pancreatic epithelial cell structure and function. Pancreas. 2004;29:77\u201383.","journal-title":"Pancreas"},{"key":"2587_CR38","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00006676-200410000-00004","volume":"29","author":"P Loukopoulos","year":"2004","unstructured":"Loukopoulos P, et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas. 2004;29:193\u2013203.","journal-title":"Pancreas"},{"key":"2587_CR39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","volume":"39","author":"L Emily","year":"2010","unstructured":"Emily L, Deer M, et al. Phenotype and genotype of pancreatic cancer. Pancreas. 2010;39:425\u201335.","journal-title":"Pancreas"},{"key":"2587_CR40","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783\u20134.","journal-title":"Nat Methods"},{"issue":"12","key":"2587_CR41","first-page":"1","volume":"15","author":"XS Liu","year":"2014","unstructured":"Liu XS, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 2014;15(12):1\u201312.","journal-title":"Genome Biol"},{"key":"2587_CR42","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2015.125","volume":"35","author":"AM Petrilli","year":"2016","unstructured":"Petrilli AM, Fern\u00e1ndez-Valle C. Role of merlin\/NF2 inactivation in tumor biology. Oncogene. 2016;35:537\u201348.","journal-title":"Oncogene"},{"key":"2587_CR43","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-14-1952","volume":"75","author":"M Quan","year":"2015","unstructured":"Quan M, et al. Merlin\/NF2 suppresses pancreatic tumor growth and metastasis by attenuating the FOXM1-mediated Wnt\/\u03b2-catenin signaling. Cancer Res. 2015;75:4778\u201389.","journal-title":"Cancer Res"},{"key":"2587_CR44","doi-asserted-by":"crossref","unstructured":"Zhao S, et al. MIEF2 reprograms lipid metabolism to drive progression of ovarian cancer through ROS\/AKT\/mTOR signaling pathway. Cell Death Dis. 2021;12.","DOI":"10.1038\/s41419-020-03336-6"},{"key":"2587_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-020-01802-9","volume":"39","author":"S Zhao","year":"2020","unstructured":"Zhao S, et al. MIEF2 over-expression promotes tumor growth and metastasis through reprogramming of glucose metabolism in ovarian cancer. J Exp Clin Cancer Res. 2020;39:1\u201315.","journal-title":"J Exp Clin Cancer Res"},{"key":"2587_CR46","doi-asserted-by":"publisher","first-page":"5106","DOI":"10.1096\/fj.201903117R","volume":"34","author":"A Dasgupta","year":"2020","unstructured":"Dasgupta A, et al. An epigenetic increase in mitochondrial fission by MiD49 and MiD51 regulates the cell cycle in cancer: diagnostic and therapeutic implications. FASEB J. 2020;34:5106\u201327.","journal-title":"FASEB J"},{"key":"2587_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2022.881487","volume":"12","author":"C Xie","year":"2022","unstructured":"Xie C, et al. CRISPR-based knockout screening identifies the loss of MIEF2 to enhance oxaliplatin resistance in colorectal cancer through inhibiting the mitochondrial apoptosis pathway. Front Oncol. 2022;12:1\u201313.","journal-title":"Front Oncol"},{"key":"2587_CR48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1126\/science.aac7041","volume":"350","author":"T Wang","year":"2015","unstructured":"Wang T, et al. Identification and characterization of essential genes in the human genome. Science. 2015;350:1096\u2013101.","journal-title":"Science"},{"key":"2587_CR49","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u20137.","journal-title":"Nucleic Acids Res"},{"key":"2587_CR50","doi-asserted-by":"publisher","first-page":"12649","DOI":"10.1073\/pnas.1307218110","volume":"110","author":"X Jiang","year":"2013","unstructured":"Jiang X, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2013;110:12649\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2587_CR51","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nm.4219","volume":"23","author":"Z Steinhart","year":"2017","unstructured":"Steinhart Z, et al. Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Nat Med. 2017;23:60\u20138.","journal-title":"Nat Med"},{"key":"2587_CR52","doi-asserted-by":"publisher","unstructured":"Rafehi H, et al. Clonogenic assay: adherent cells. J Vis Exp. 2011:15\u201317. https:\/\/doi.org\/10.3791\/2573.","DOI":"10.3791\/2573"},{"key":"2587_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1371\/journal.pone.0092444","volume":"9","author":"C Guzm\u00e1n","year":"2014","unstructured":"Guzm\u00e1n C, Bagga M, Kaur A, Westermarck J, Abankwa D. Colonyarea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS ONE. 2014;9:14\u20137.","journal-title":"PLoS ONE"},{"key":"2587_CR54","first-page":"7784","volume":"10","author":"J Feng","year":"2017","unstructured":"Feng J, et al. High expression of heat shock protein 10 (Hsp10) is associated with poor prognosis in oral squamous cell carcinoma. Int J Clin Exp Pathol. 2017;10:7784\u201391.","journal-title":"Int J Clin Exp Pathol"},{"key":"2587_CR55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.humpath.2016.09.039","volume":"61","author":"S Chu","year":"2017","unstructured":"Chu S, et al. High expression of heat shock protein 10 correlates negatively with estrogen\/progesterone receptor status and predicts poor prognosis in invasive ductal breast carcinoma. Hum Pathol. 2017;61:173\u201380.","journal-title":"Hum Pathol"},{"key":"2587_CR56","doi-asserted-by":"publisher","first-page":"8219","DOI":"10.2147\/CMAR.S218427","volume":"11","author":"J Feng","year":"2019","unstructured":"Feng J, et al. Increased expression of heat shock protein (HSP) 10 and HSP70 correlates with poor prognosis of nasopharyngeal carcinoma. Cancer Manag Res. 2019;11:8219\u201327.","journal-title":"Cancer Manag Res"},{"key":"2587_CR57","first-page":"1325","volume":"23","author":"F Cappello","year":"2003","unstructured":"Cappello F, Rappa F, David S, Anzalone R, Zummo G. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis. Anticancer Res. 2003;23:1325\u201331.","journal-title":"Anticancer Res"},{"key":"2587_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/CBM-200410","volume":"30","author":"Y Tang","year":"2021","unstructured":"Tang Y, et al. Overexpression of HSP10 correlates with HSP60 and Mcl-1 levels and predicts poor prognosis in non-small cell lung cancer patients. Cancer Biomark. 2021;30:85\u201394.","journal-title":"Cancer Biomark"},{"key":"2587_CR59","doi-asserted-by":"crossref","unstructured":"Ye Y, et al. Comparative mitochondrial proteomic analysis of hepatocellular carcinoma from patients. Proteomics Clin Appl. 2013;7.","DOI":"10.1002\/prca.201100103"},{"key":"2587_CR60","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1002\/pmic.200500427","volume":"6","author":"C Melle","year":"2006","unstructured":"Melle C, et al. Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling. Proteomics. 2006;6:2600\u20138.","journal-title":"Proteomics"},{"key":"2587_CR61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0304-3835(03)00212-X","volume":"196","author":"F Cappello","year":"2003","unstructured":"Cappello F, Bellafiore M, David S, Anzalone R, Zummo G. Ten kilodalton heat shock protein (HSP10) is overexpressed during carcinogenesis of large bowel and uterine exocervix. Cancer Lett. 2003;196:35\u201341.","journal-title":"Cancer Lett"},{"key":"2587_CR62","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ygyno.2005.11.014","volume":"101","author":"S Akyol","year":"2006","unstructured":"Akyol S, Gercel-Taylor C, Reynolds LC, Taylor DD. HSP-10 in ovarian cancer: expression and suppression of T-cell signaling. Gynecol Oncol. 2006;101:481\u20136.","journal-title":"Gynecol Oncol"},{"key":"2587_CR63","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1146\/annurev.cellbio.23.090506.123555","volume":"23","author":"AL Horwich","year":"2007","unstructured":"Horwich AL, Fenton WA, Chapman E, Farr GW. Two families of chaperonin: physiology and mechanism. Annu Rev Cell Dev Biol. 2007;23:115\u201345.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2587_CR64","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/carcin\/bgp087","volume":"30","author":"YP Tsai","year":"2009","unstructured":"Tsai YP, et al. Interaction between HSP60 and \u03b2-catenin promotes metastasis. Carcinogenesis. 2009;30:1049\u201357.","journal-title":"Carcinogenesis"},{"key":"2587_CR65","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ceb.2007.02.007","volume":"19","author":"R Fodde","year":"2007","unstructured":"Fodde R, Brabletz T. Wnt\/\u03b2-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007;19:150\u20138.","journal-title":"Curr Opin Cell Biol"},{"key":"2587_CR66","doi-asserted-by":"publisher","first-page":"13171","DOI":"10.1038\/ncomms13171","volume":"7","author":"E Berger","year":"2016","unstructured":"Berger E, et al. Mitochondrial function controls intestinal epithelial stemness and proliferation. Nat Commun. 2016;7:13171.","journal-title":"Nat Commun"},{"key":"2587_CR67","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1002\/cncr.22265","volume":"107","author":"F Cappello","year":"2006","unstructured":"Cappello F, et al. Hsp60 and hsp10 down-regulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease. Cancer. 2006;107:2417\u201324.","journal-title":"Cancer"},{"key":"2587_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-5-139","volume":"5","author":"F Cappello","year":"2005","unstructured":"Cappello F, et al. The expression of Hsp60 and Hsp10 in large bowel carcinomas with lymph node metastases. BMC Cancer. 2005;5:1\u201310.","journal-title":"BMC Cancer"},{"key":"2587_CR69","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1074\/jbc.M705904200","volume":"283","author":"JC Ghosh","year":"2008","unstructured":"Ghosh JC, Dohi T, Byoung HK, Altieri DC. Hsp60 regulation of tumor cell apoptosis. J Biol Chem. 2008;283:5188\u201394.","journal-title":"J Biol Chem"},{"key":"2587_CR70","doi-asserted-by":"crossref","unstructured":"Polson ES, et al. KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice. Sci Transl Med. 2018;10.","DOI":"10.1126\/scitranslmed.aar2718"},{"key":"2587_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02049-8","volume":"40","author":"B Parma","year":"2021","unstructured":"Parma B, et al. Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting. J Exp Clin Cancer Res. 2021;40:1\u201320.","journal-title":"J Exp Clin Cancer Res"},{"key":"2587_CR72","doi-asserted-by":"crossref","unstructured":"Orellana E, Kasinski A. Sulforhodamine B (SRB) assay in cell culture to investigate cell proliferation. Bio-Protocol. 2016;6.","DOI":"10.21769\/BioProtoc.1984"},{"key":"2587_CR73","doi-asserted-by":"publisher","first-page":"106067","DOI":"10.1016\/j.isci.2023.106067","volume":"26","author":"N Yeung","year":"2023","unstructured":"Yeung N, Murata D, Iijima M, Sesaki H. Role of human HSPE1 for OPA1 processing independent of HSPD1. iScience. 2023;26:106067.","journal-title":"iScience"},{"key":"2587_CR74","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1083\/jcb.200906083","volume":"187","author":"B Head","year":"2009","unstructured":"Head B, Griparic L, Amiri M, Gandre-Babbe S, Van Der Bliek AM. Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. J Cell Biol. 2009;187:959\u201366.","journal-title":"J Cell Biol"},{"key":"2587_CR75","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1083\/jcb.200906084","volume":"187","author":"S Ehses","year":"2009","unstructured":"Ehses S, et al. Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1. J Cell Biol. 2009;187:1023\u201336.","journal-title":"J Cell Biol"},{"key":"2587_CR76","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbabio.2018.01.005","volume":"1859","author":"V Del Dotto","year":"2018","unstructured":"Del Dotto V, Fogazza M, Carelli V, Rugolo M, Zanna C. Eight human OPA1 isoforms, long and short: what are they for? Biochim Biophys Acta Bioenerg. 2018;1859:263\u20139.","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"2587_CR77","doi-asserted-by":"publisher","first-page":"7743","DOI":"10.1074\/jbc.C200677200","volume":"278","author":"A Olichon","year":"2003","unstructured":"Olichon A, et al. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem. 2003;278:7743\u20136.","journal-title":"J Biol Chem"},{"key":"2587_CR78","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/sj.cdd.4402048","volume":"14","author":"A Olichon","year":"2007","unstructured":"Olichon A, et al. OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis. Cell Death Differ. 2007;14:682\u201392.","journal-title":"Cell Death Differ"},{"key":"2587_CR79","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1242\/jcs.159186","volume":"129","author":"T MacVicar","year":"2016","unstructured":"MacVicar T, Langer T. OPA1 processing in cell death and disease - the long and short of it. J Cell Sci. 2016;129:2297\u2013306.","journal-title":"J Cell Sci"},{"key":"2587_CR80","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, et al. Combination therapy in combating cancer. Oncotarget. 2017;8:38022\u201343.","journal-title":"Oncotarget"},{"key":"2587_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-024-02029-4","volume":"23","author":"S Poulet","year":"2024","unstructured":"Poulet S, et al. Genome-wide in vivo CRISPR screen identifies TGF\u03b23 as actionable biomarker of palbociclib resistance in triple negative breast cancer. Mol Cancer. 2024;23:1\u201321.","journal-title":"Mol Cancer"},{"key":"2587_CR82","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. Synergyfinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u201343.","journal-title":"Nucleic Acids Res"},{"key":"2587_CR83","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1023\/A:1008213732429","volume":"9","author":"E Raymond","year":"1998","unstructured":"Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053\u201371.","journal-title":"Ann Oncol"},{"key":"2587_CR84","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/1471-2407-13-194","volume":"13","author":"MT Yip-Schneider","year":"2013","unstructured":"Yip-Schneider MT, et al. Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013;13:194.","journal-title":"BMC Cancer"},{"key":"2587_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9010060","volume":"9","author":"CW Yun","year":"2019","unstructured":"Yun CW, Kim HJ, Lim JH, Lee SH. Heat shock proteins: agents of cancer development and therapeutic targets in anti-cancer therapy. Cells. 2019;9:1\u201330.","journal-title":"Cells"},{"key":"2587_CR86","doi-asserted-by":"publisher","first-page":"115096","DOI":"10.1016\/j.bcp.2022.115096","volume":"201","author":"Y Tang","year":"2022","unstructured":"Tang Y, Zhou Y, Fan S, Wen Q. The multiple roles and therapeutic potential of HSP60 in cancer. Biochem Pharmacol. 2022;201:115096.","journal-title":"Biochem Pharmacol"},{"key":"2587_CR87","doi-asserted-by":"publisher","first-page":"155798832413069","DOI":"10.1177\/15579883241306904","volume":"18","author":"J Cheng","year":"2024","unstructured":"Cheng J, et al. Hspe1 inhibits bladder cancer ferroptosis via a glutathione-dependent mechanism by suppressing GPX4. Am J Mens Health. 2024;18:15579883241306904.","journal-title":"Am J Mens Health"},{"key":"2587_CR88","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1083\/jcb.126.2.305","volume":"126","author":"J H\u00f6hfeld","year":"1994","unstructured":"H\u00f6hfeld J, Hartl FU. Role of the chaperonin cofactor Hsp10 in protein folding and sorting in yeast mitochondria. J Cell Biol. 1994;126:305\u201315.","journal-title":"J Cell Biol"},{"key":"2587_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmolb.2018.00035","volume":"5","author":"Q Meng","year":"2018","unstructured":"Meng Q, Li BX, Xiao X. Toward developing chemical modulators of Hsp60 as potential therapeutics. Front Mol Biosci. 2018;5:1\u201311.","journal-title":"Front Mol Biosci"},{"key":"2587_CR90","doi-asserted-by":"publisher","first-page":"16542","DOI":"10.1073\/pnas.1010300107","volume":"107","author":"H Wurdak","year":"2010","unstructured":"Wurdak H, et al. A small molecule accelerates neuronal differentiation in the adult rat. Proc Natl Acad Sci U S A. 2010;107:16542\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2587_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-022-02304-6","volume":"41","author":"M Zamberlan","year":"2022","unstructured":"Zamberlan M, et al. Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth. J Exp Clin Cancer Res. 2022;41:1\u201318.","journal-title":"J Exp Clin Cancer Res"},{"key":"2587_CR92","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.3748\/wjg.v28.i28.3637","volume":"28","author":"A Nishimoto","year":"2022","unstructured":"Nishimoto A. Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World J Gastroenterol. 2022;28:3637\u201343.","journal-title":"World J Gastroenterol"},{"key":"2587_CR93","first-page":"1","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju Y, et al. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol. 2024;8:1\u201318.","journal-title":"NPJ Precis Oncol"},{"key":"2587_CR94","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41588-024-01790-y","volume":"56","author":"D Maia-Silva","year":"2024","unstructured":"Maia-Silva D, et al. Interaction between MED12 and \u0394Np63 activates basal identity in pancreatic ductal adenocarcinoma. Nat Genet. 2024;56:1377\u201385.","journal-title":"Nat Genet"},{"key":"2587_CR95","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/s44321-024-00060-y","volume":"16","author":"S Wang","year":"2024","unstructured":"Wang S, et al. Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. EMBO Mol Med. 2024;16:1115\u201342.","journal-title":"EMBO Mol Med"},{"key":"2587_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-49450-3","volume":"15","author":"S Martinez","year":"2024","unstructured":"Martinez S, et al. In vivo CRISPR screens reveal SCAF1 and USP15 as drivers of pancreatic cancer. Nat Commun. 2024;15:1\u201315.","journal-title":"Nat Commun"},{"key":"2587_CR97","doi-asserted-by":"publisher","unstructured":"Lee DK, Loke R, Chow JT, Gabra MM, Salmena L. Phosphoinositide-focused CRISPR screen identifies novel genetic vulnerabilities in PDAC and AML cells. 2024. https:\/\/doi.org\/10.1101\/2024.09.09.612071.","DOI":"10.1101\/2024.09.09.612071"},{"key":"2587_CR98","doi-asserted-by":"crossref","unstructured":"Oktriani R, et al. Genome-wide CRISPR screen identifies genes involved in metastasis of pancreatic ductal adenocarcinoma. Cancers (Basel). 2024;16.","DOI":"10.3390\/cancers16213684"},{"key":"2587_CR99","doi-asserted-by":"publisher","first-page":"101964","DOI":"10.1016\/j.molmet.2024.101964","volume":"85","author":"CS Kubota","year":"2024","unstructured":"Kubota CS, Myers SL, Sepp\u00e4l\u00e4 TT, Burkhart RA, Espenshade PJ. In vivo CRISPR screening identifies geranylgeranyl diphosphate as a pancreatic cancer tumor growth dependency. Mol Metab. 2024;85:101964.","journal-title":"Mol Metab"},{"key":"2587_CR100","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41596-018-0113-7","volume":"14","author":"B Wang","year":"2019","unstructured":"Wang B, et al. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat Protoc. 2019;14:756\u201380.","journal-title":"Nat Protoc"},{"key":"2587_CR101","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.fct.2005.03.007","volume":"43","author":"S Gould","year":"2005","unstructured":"Gould S, Scott RC. 2-hydroxypropyl-\u03b2-cyclodextrin (HP-\u03b2-CD): a toxicology review. Food Chem Toxicol. 2005;43:1451\u20139.","journal-title":"Food Chem Toxicol"},{"key":"2587_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:1\u20137.","journal-title":"Sci Rep"},{"key":"2587_CR103","doi-asserted-by":"crossref","unstructured":"Klaiber U, Hackert T, Neoptolemos JP. Adjuvant treatment for pancreatic cancer. Transl Gastroenterol Hepatol. 2019;4.","DOI":"10.21037\/tgh.2019.04.04"},{"key":"2587_CR104","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.clinthera.2017.08.015","volume":"39","author":"MT Saung","year":"2017","unstructured":"Saung MT, Zheng L. Current standards of chemotherapy for pancreatic cancer. Clin Ther. 2017;39:2125\u201334.","journal-title":"Clin Ther"},{"key":"2587_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13040799","volume":"13","author":"C Leroux","year":"2021","unstructured":"Leroux C, Konstantinidou G. Targeted therapies for pancreatic cancer: overview of current treatments and new opportunities for personalized oncology. Cancers (Basel). 2021;13:1\u201328.","journal-title":"Cancers (Basel)"},{"key":"2587_CR106","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/14728214.2022.2134346","volume":"27","author":"U Rudloff","year":"2022","unstructured":"Rudloff U. Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. Expert Opin Emerg Drugs. 2022;27:345\u201368.","journal-title":"Expert Opin Emerg Drugs"},{"key":"2587_CR107","doi-asserted-by":"crossref","unstructured":"Gomez-Llorente Y, et al. Structural basis for active single and double ring complexes in human mitochondrial Hsp60-Hsp10 chaperonin. Nat Commun. 2020;11.","DOI":"10.1038\/s41467-020-15698-8"},{"key":"2587_CR108","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.3390\/cimb46040177","volume":"46","author":"D Stefanoudakis","year":"2024","unstructured":"Stefanoudakis D, et al. Significance of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer. Curr Issues Mol Biol. 2024;46:2827\u201344.","journal-title":"Curr Issues Mol Biol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02587-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02587-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02587-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:04:13Z","timestamp":1773065053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02587-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":108,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2587"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02587-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animals were housed and handled in accordance with the approved guidelines of the Canadian Council on Animal Care (CCAC) \u201cGuide to the Care and Use of Experimental Animals\u201d. All experiments were performed in accordance with the approved McGill University Animal Care protocol (AUP # 7497 to JJL).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}